Peter Zdziarski: Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
Peter Zdziarski, Vice President and Marketing Director at the Glanzmann’s Research Foundation, shared a post on LinkedIn:
”Gene Therapy vs Prophylaxis in Glanzmann Thrombasthenia
This is one of the most frequently asked questions I hear from the GT community, and it’s a crucial one.
The distinction matters:
Prophylaxis requires ongoing drug use, often weekly or bi-weekly.
Gene therapy is designed as a single procedure and has the potential for a lasting solution.
What’s important to remember is that both options are still in clinical trials. Marketing to the GT community has put a heavy spotlight on prophylaxis in recent years. For many families, this has made it seem like the only new option, when in fact gene therapy for GT has been in development for years.
That’s why staying informed is so critical. There is meaningful research happening that could change the future of treatment. Both options, and the realities behind them, deserve attention.
If you or a loved one is living with GT, I strongly encourage you to follow the groundbreaking work of Dr. David Wilcox and his team at the Medical College of Wisconsin. Their efforts are bringing real hope for a long-term solution to Glanzmann Thrombasthenia.
Knowledge is power. The more we understand the science, the costs, and the possibilities, the better prepared we are to make the best decisions for our community’s future.”
Find more information here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team